Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.31 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298965 | 1.00 | SLC6A4 (0.38) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3302192 | 1.00 | SLC6A4 (0.38) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3298961 | 1.00 | SLC6A4 (0.38) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3297878 | 0.81 | SLC6A4 (0.39) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3297637 | 0.81 | SLC6A4 (0.39) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3297642 | 0.81 | SLC6A4 (0.39) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3299919 | 0.81 | SLC6A4 (0.39) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3302137 | 0.78 | SLC6A4 (0.36) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL3302138 | 0.78 | SLC6A4 (0.36) | SLC6A4HTR2CHTR2BSLC6A3SLC6A2 | |
| SCHEMBL6310527 | 0.67 | HTR2A (0.34) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SLC6A4, SLC18A2, SLC6A2 | SLC6A4 1/4885HTR2C 52/4885HTR2B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.